Table 2.

Crude response rates at 1 year of treatment with a first TNF inhibitor after stratification for different BMI categories

		BMI category
Outcome	n = 531	Normal n = 282	Overweight n = 178	Obese n = 71	p
ASAS40	494	44%	34%	29%	0.02
ASAS40 TNFi other than INF	383	45%	34%	24%	0.008
ASAS40 TNFi: INF	111	42%	36%	44%	0.83
ASAS partial remission	531	39%	24%	17%	<0.001
BASDAI-50	488	48%	40%	33%	0.06
ASDAS improvement ≥1.1	423	59%	46%	37%	0.003
ASDAS <2.1	468	56%	41%	25%	<0.001
ASDAS improvement ≥2	423	25%	25%	13%	0.14
ASDAS <1.3	468	29%	15%	10%	<0.001

Normal weight = BMI 18.5–25; overweight = BMI 25–30; obese = BMI >30

ASAS Assessment in SpondyloArthritis International Society, ASAS40 40% improvement according to ASAS, ASDAS Ankylosing Spondylitis Disease Activity Score, BASDAI-50 50% improvement in Bath Ankylosing Spondylitis Disease Activity Index, BMI body mass index, INF infliximab, TNFi tumor necrosis factor inhibitor